依帕司他联合α-硫辛酸方案用于糖尿病周围神经病变的可行性及预后分析

Feasibility and prognostic analysis of epalrestat combined withα-lipoic acidin the treatment of diabetic peripheral neuropathy

目的探讨对糖尿病周围神经病变患者实施依帕司他联合α-硫辛酸方案的效果,为临床提供指导。方法采用计算机随机分组法将2016年1月~2018年4月我院86例糖尿病周围神经病变患者分为观察组(43例,采用依帕司他联合α-硫辛酸治疗)、对照组(43例,采用依帕司他治疗)。比较两组患者的疗效、氧化应激指标、腓总神经传导速度、正中神经传导速度、炎症因子水平及不良反应发生情况。结果(1)在总有效率方面,观察组(86.05%)高于对照组(62.79%),P<0.05;(2)观察组患者治疗后SOD[(36.15±2.85)U/mL]高于对照组[(31.35±2.41)U/mL],且MDA[(3.23±0.23)nmol/mL]低于对照组[(4.78±0.42)nmol/mL],P<0.05;(3)观察组患者治疗后IL-6[(10.23±2.23)pg/L]、CRP[(8.15±2.10)mg/L]低于对照组,P<0.05;(4)观察组患者治疗后腓总神经、正中神经传导速度均高于对照组,P<0.05;(5)治疗期间,两组患者均未出现明显不良反应。结论对糖尿病周围神经病变患者实施依帕司他联合α-硫辛酸方案治疗十分可行,能有效改善周围神经病变情况。

Objective To explore the effect of epalrestat combined with α-lipoic acidin the patients with diabetic peripheral neuropathy. Methods From January 2016 to April 2018, 86 patients with diabetic peripheral neuropathy in our hospital were randomly divided into observation group (43 cases, treated with epalrestat and α-lipoic acid) and control group (43 cases, treated with epalrestat).The therapeutic effect, oxidative stress index, common peroneal nerve conduction velocity, median nerve conduction velocity, inflammatory factor level and adverse reaction were compared between the two groups. Results (1) The total effective rate in the observation group (86.05%) was higher thanthe control group (62.79%), P < 0.05.(2) After treatment, SOD [(36.15±2.85) U/mL] in the observation group were significantly higher than the control group [(31.35±2.41) U/mL],MDA[(3.23±0.23) nmol/mL] was lower than the control group [(4.78±0.42) nmol/mL],P < 0.05.(3) After treatment, IL-6 [(10.23±2.23) pg/L] and CRP [(8.15±2.10) mg/L] in the observation group were lower than the control group (P < 0.05).(4) The conduction velocity of common peroneal nerve and median nerve in the observation group were higher than the control group (P < 0.05).(5) During the treatment, there were no obvious adverse reactions in both groups. Conclusion It is feasible to treat diabetic peripheral neuropathy patients with epalrestat combined with α-lipoic acid regimen, which can effectively improve the condition of peripheral neuropathy.